Century Therapeutics (IPSC) Cash from Financing Activities (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Cash from Financing Activities data on file, last reported at $126.6 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $126.6 million, up 105419.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $126.7 million (up 124.25% YoY), and the FY2025 annual result was $173000.0, down 99.77% from the prior year.
• Cash from Financing Activities grew to $126.6 million in Q1 2026 per IPSC's latest filing, from $53000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $126.6 million in Q1 2026 and troughed at -$10.1 million in Q2 2023.
• A 5-year average of $14.6 million and a median of $137000.0 in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities plunged 21177.08% in 2023, then jumped 105419.17% in 2026.
• A 5-year view of Cash from Financing Activities shows it stood at $95000.0 in 2022, then sank by 474.74% to -$356000.0 in 2023, then plunged by 69.1% to -$602000.0 in 2024, then surged by 108.8% to $53000.0 in 2025, then surged by 238811.32% to $126.6 million in 2026.
• Business Quant data shows IPSC's Cash from Financing Activities at $126.6 million in Q1 2026, $53000.0 in Q4 2025, and $120000.0 in Q1 2025.